This site is intended for healthcare professionals

FDA approves Triumeq PD formulation for pediatric treatment of HIV plus a supplemental approval for Triumeg.- ViiV Healthcare

Read time: 1 mins
Published:1st Apr 2022

ViiV Healthcare announced that the FDA has approved a new drug application (NDA) for Triumeq PD, a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine for the treatment of pediatric patients weighing 10kgs to <25 kgs with human immunodeficiency virus type 1 (hiv-1).

In addition, a supplemental new drug application (sNDA) has been approved for Triumeq tablet, lowering the minimum weight that a child with human immunodeficiency virus type 1 (HIV-1) can be prescribed this medicine to 25kgs from 40kgs.

Condition: HIV/AIDS
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights